Biogen (NASDAQ: BIIB) reported a 12% increase in adjusted EPS and 2% growth in revenue for the second quarter of 2020. Adjusted EPS of $10.26 and revenue of $3.68 billion in the quarter were better than analysts’ estimates. Shares of Biogen rose about 3% in the pre-market trading session.
While Biogen lifted its EPS guidance for fiscal 2020, it lowered the revenue expectations.
The company lifted FY20 GAAP EPS outlook to a range of $32.00 and $34.00 from the prior guidance range of $29.50 to $31.50. Non-GAAP EPS is now expected to be between $34.00 and $36.00 versus a prior range of $31.50 to $33.50.
Revenue outlook for FY20 is cut down to a range of $13.8 billion to $14.2 billion from the prior expected range of $14.0 billion to $14.3 billion.
Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to
Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming
The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related